Swedish Orphan Biovitrum

Swedish Orphan Biovitrum's reported carbon emissions

Swedish Orphan Biovitrum (Sobi), a pharmaceutical preparation manufacturer headquartered in Sweden, reported total greenhouse gas emissions of approximately 303,768,000 kg CO2e for the reporting year 2025. This figure encompasses Scope 1, 2, and 3 emissions. **Emissions Breakdown (2025):** * **Scope 1:** Approximately 932,000 kg CO2e * **Scope 2 (Market-based):** Approximately 533,000 kg CO2e * **Scope 3:** Approximately 302,303,000 kg CO2e, with purchased goods and services being the largest contributor at about 282,832,000 kg CO2e. **Climate Commitments and Reduction Targets:** Sobi has established several climate reduction targets: * **Near-term Combined Scope 1 and 2 Target:** Sobi is committed to an absolute reduction of 37.8% in combined Scope 1 and 2 emissions by 2029, using 2023 as the base year. This target is aligned with a 1.5°C warming scenario. * **Long-term Net Zero Goal:** Sobi aims to achieve net-zero operational greenhouse gas emissions by 2030 for its facilities and fleet. * **Scope 1 and 2 Reduction Target (Previous):** Previously, Sobi had a target to reduce its operational GHG footprint by 50% from a 2015 baseline by 2025 for both Scope 1 and Scope 2 emissions. The company's emissions data is not cascaded from a parent organisation, indicating direct reporting. Sobi's commitment to science-based targets also extends to its supply chain, with a goal for 65% of its suppliers (by spend) in purchased goods and services, and upstream transportation and distribution, to have science-based targets by 2029.